Purpose: Establishing reliable methods for interpreting elevated cerebral amyloid-β plaque on PET scans is increasingly important for radiologists, as availability of PET imaging in clinical practice increases. We examined a 3-step method to detect plaque in cognitively normal older adults, focusing on the additive value of quantitative information during the PET scan interpretation process. Methods: Fifty-five 18 F-florbetapir PET scans were evaluated by 3 experienced raters. Scans were first visually interpreted as having "elevated" or "nonelevated" plaque burden ("Visual Read"). Images were then processed using a standardized quantitative analysis software (MIMneuro) to generate whole brain and region of interest SUV ratios. This "Quantitative Read" was considered elevated if at least 2 of 6 regions of interest had an SUV ratio of more than 1.1. The final interpretation combined both visual and quantitative data together ("VisQ Read"). Cohen kappa values were assessed as a measure of interpretation agreement. Results: Plaque was elevated in 25.5% to 29.1% of the 165 total Visual Reads. Interrater agreement was strong (kappa = 0.73-0.82) and consistent with reported values. Quantitative Reads were elevated in 45.5% of participants. Final VisQ Reads changed from initial Visual Reads in 16 interpretations (9.7%), with most changing from "nonelevated" Visual Reads to "elevated." These changed interpretations demonstrated lower plaque quantification than those initially read as "elevated" that remained unchanged. Interrater variability improved for VisQ Reads with the addition of quantitative information (kappa = 0.88-0.96).
A lzheimer disease (AD) is a growing concern in the United States; over 5 million Americans are currently affected by the disease, with an expected tripling in prevalence by 2050. 1 While diagnosis is now largely based upon clinical data, the 2011 revision of AD diagnostic criteria calls for the incorporation of biomarkers into the diagnostic algorithm. 2 In addition, new PET imaging techniques are now capable of detecting AD-relevant molecular changes, including the hallmark pathologies of amyloid-β plaques and neurofibrillary tangles, making it likely these imaging techniques will play an important role in future efforts to detect and diagnose the disease. 3 Three radiopharmaceuticals are currently Food and Drug Administration (FDA)-approved to detect amyloid-β plaques (florbetapir, flutemetamol, and florbetaben), and new compounds targeting other features of the disease, such as tau, are expected to reach market in the near future. 4, 5 Radiologic interpretation of amyloid-β PET imaging, however, has demonstrated significant interreader variability. 6 As such, the initial FDA approval of the first radiotracer, florbetapir, was delayed until training methodologies were developed to reduce variability in interpreting amyloid-β plaque burden. 7 Although significant interreader variability remains (reported kappa coefficients range, 0.40-0.89), these FDA-approved methods have demonstrated adequate sensitivity for plaque detection with validation in cohorts of individuals with postmortem autopsies. 6, [8] [9] [10] Because the clinical implications of an elevated scan are significant, a highly robust and reproducible method of interpretation is important. Development of meaningful quantitative PET imaging measures, such as using SUV ratios (SUVRs), has an important clinical and research role, such as monitoring changes in amyloid-β plaque burden over time in longitudinal studies testing therapeutic interventions. 11, 12 The development of a reliable binary interpretation measure ("elevated" vs "nonelevated" amyloid-β plaque burden) remains the most clinically relevant measure for practicing radiologists and clinicians. Thus, the importance of an accurate and reproducible interpretation method of PET imaging is essential as the clinical use of amyloid-β PET scans becomes widespread.
Reliable detection of amyloid-β plaque before cognitive decline may be important, as new clinical treatment strategies that are currently in development that may disrupt or remove these plaques. 13 It is our experience that in patients with extensive plaque deposition, the visual interpretation of amyloid-β PET scans is usually not difficult. However, visual detection of plaque when confined to only a few areas is more challenging. Therefore, we developed and tested a systematic PET interpretation process that included both qualitative and quantitative assessment of amyloid-β plaque burden in an effort to improve the consistency of detection of early plaque deposition in cognitively normal older adults to identify individuals who may be at higher risk for developing AD.
PATIENTS AND METHODS
We analyzed amyloid-β PET brain images from a small cohort of cognitively normal participants in ongoing AD prevention studies at our institution from August 1, 2011, to July 31, 2014. Subjects were administered IV Three experienced raters interpreted all images. Raters were a radiologist (rater 1), a neurologist (rater 2), and a neuroscience researcher (rater 3), each with at least 1 year of experience in florbetapir PET interpretation. Each rater completed the FDAapproved training program for florbetapir interpretation, 14 which consisted of Web-based lectures and training scans. MIMneuro software (MiM Software Inc, Cleveland, OH) was used to visualize, quantify plaque burden, and process the images. Each rater participated in all 3 steps of the systematic PET interpretation process (Fig. 1) . First, the raters independently reviewed the raw amyloid-β PET images and qualitatively determined whether the scan was elevated or nonelevated ("Visual Read"). Visual Reads were completed according to the manufacturer's training methods and before having access to or knowledge of quantitative analyses of amyloid-β plaque burden. Scans determined to be elevated on the Visual Read were defined as having either (1) 2 or more areas of loss of gray-white matter differentiation larger than the cortical gyrus, or (2) 1 large area of gray matter uptake that clearly exceeded the adjacent white matter.
Second, MIMneuro software quantitatively compared the mean uptake in 6 regions of interest (ROIs) on the amyloid-β PET images to each patient's mean whole cerebellum uptake, resulting in SUVRs for these 6 ROIs: anterior cingulate, posterior cingulate, precuneus, inferior medial frontal, lateral temporal, and superior parietal cortex. Each rater then used this quantitative data to classify each scan as elevated or nonelevated using a definition of 2 or more regions with mean SUVRs greater than 1.1. This cut point is consistent with previous imaging data using SUVRs of these same 6 regions that were correlated with autopsy measures. 9, 10 Because the Visual Read required 2 or more areas of loss of gray-white matter differentiation, we chose a similar quantification cutoff of 2 or more of the 6 regions having SUVRs of 1.1 or greater.
In addition to providing SUVR analyses, MIMneuro also generated 3 supplementary analyses: region, voxel, and cortical projections (MIMneuro User Guide 6.2). To perform these analyses, each subject's brain was mapped to a standard template space using a multitemplate landmark-based deformable image registration (MIMneuro User Guide 6.2). After spatial normalization, each subject was compared on a voxel-by-voxel and regional basis to a database of 74 expert confirmed amyloid negative "normal" florbetapir PET brain scans (48 men, 26 women) between the ages of 18 to 50 years. Z-scores, or the number of standard deviations away from the mean of the normal database, were calculated for each voxel in the brain and for the same 6 regions used in the SUVR analysis. Z-score results were displayed fused with the registered FIGURE 1. Three-step method for interpretation of florbetapir PET scans utilizing Visual Read, Quantitative Read, and VisQ Reads.
Step 1: rater performs a Visual Read of the PET images.
Step 2: Quantitative Read is produced using MIMneuro with uptake analysis in 6 regions. Region is elevated if SUVR is >1.10.
Step 3: VisQ interpretation is produced by the rater after summation of the Visual and Quantitative Reads. A, PET images with fused voxel analysis Z-scores of uptake of flobetapir normalized to the patient's cerebellum. SUVR data are calculated from the computer-drawn ROI, exemplified here as the blue ROI in the precuneus. B, 3D surface maps of similar data fusing raw PET data with calculated uptake Z-scores. C, Example raw PET images are presented in black and white, as well as with rainbow color scale, to exemplify a loss of gray-white differentiation in the right parietal lobe (red arrows).
brain scan (Fig. 1, step 3 , panels A and B). Voxels with a Z-score greater than 3 were color highlighted based on previous analyses demonstrating this value correlated most strongly with expert reads. Z-score values were also displayed for each of the 6 ROIs. Cortical surface projections were generated by sampling a probabilistic gray matter mask for the highest uptake voxel along vectors perpendicular to the surface of the brain. Z-scores from the cortical projection images were also evaluated as an additional qualitative measure of potential affected cortical regions (MIMneuro User Guide 6.2).
Finally, after viewing all quantitative data, fused images, and cortical projections, each rater then re-evaluated the raw PET images, paying close attention to ROIs demonstrating elevated SUVRs or Z-scores. Raters documented their final interpretation of the amyloid-β PET scan as elevated or nonelevated in the context of both the visual and quantitative information ("VisQ Read"). Data were managed using REDCap electronic data capture tools hosted at our institution. 15 Statistical analyses were performed using SAS 9.4 software (SAS Institute, Inc, Cary, NC) and statistical significance was determined using a P value less than 0.05. Cohen kappa was used to assess interrater agreement of reads and t tests were used to compare continuous variables such as SUVR.
RESULTS
Three raters independently interpreted 55 amyloid-β PET scans from cognitively normal participants (1 scan per participant) with an average age of 73.1 years (SD ±5.9), 56% women, and a mean Mini-Mental Status Exam (MMSE) score of 29 (SD ± 1.0). The frequency of elevated Visual Reads ranged from 25.5% to 29.1% across raters (Table 1) . Visual Read agreement across the 3 raters (Cohen kappa) ranged from 0.73 to 0.82 for this study. After reinterpreting the scans with quantitative information (VisQ Read), raters altered their initial interpretation in 16 (9.7%) of the 165 total amyloid-β PET reads, a frequency of change of 7.3% to 12.7% for individual rater's interpretations. Interrater agreement (Cohen kappa) for the final VisQ Reads improved from 0.88 to 0.96 after quantitative information was available. The majority of changes in interpretation went from nonelevated Visual Reads to elevated VisQ Reads (13 of 16 interpretations; 81.3%).
The 16 changed interpretations were from 11 participant scans. All 3 raters changed their interpretations for the same scan just once (from nonelevated to elevated; Figs. 2, 3), whereas 2 raters changed their interpretations for 3 scans and 1 rater changed interpretations for seven scans. The 8 scans with nonelevated Visual Reads that changed to elevated VisQ Reads had a mean SUVR of 1.21 (SD ±0.09) and all had 2 or more ROIs with elevated SUVRs (Table 2 ). The scans with unchanged elevated reads (n = 12) demonstrated a mean SUVR of 1.38 (SD ±0.19). None of the 3 scans with elevated Visual Reads that changed to nonelevated VisQ Reads had more than 1 ROI with an elevated SUVR, and their mean SUVR was 1.01 (SD ±0.03). This was similar to the 32 nonelevated scans for both the Visual and VisQ Reads (mean SUVR, 0.99; SD ±0.05). Based on quantitative information only (Quantitative Read), 45.5% (n = 25) of the scans met criteria for elevated cerebral amyloid-β plaque (2 or more ROIs with mean SUVRs ≥ 1.1). All nonelevated Quantitative Reads were nonelevated by both Visual and VisQ Reads. Of the 25 scans that were elevated by Quantitative Read, 44% (n = 11) were not considered elevated by Visual Read and 24% (n = 6) were not considered elevated by VisQ Read. These data suggests that Quantitative Reads alone may result in elevated interpretations more frequently than rater-dependent methods (Visual and VisQ Reads).
DISCUSSION
These data support our hypothesis that augmenting visual interpretation of amyloid-β PET scans of cognitively normal participants with quantitative information decreased the variability of rater interpretations, which is consistent with other recent studies utilizing a similar Visual Read only technique (kappa = 0.40-0.89). 6, [8] [9] [10] 12, 13, 16, 17 Our results also suggest that the addition of quantitative PET scan data is most important for the improved detection of early plaque deposition or in cases where the patient demonstrates borderline Visual or Quantitative Reads (eg, 1-2 qualitative and/or quantitative positive ROIs).
When quantitative information was provided to the raters, the frequency of an elevated cerebral amyloid-β interpretation rose slightly (from an average of 27.9% of Visual Reads to 36.4% of VisQ Reads) and interrater variability decreased, with VisQ Reads demonstrating higher interrater agreement (0.88 to 0.96), similar to a recent study utilizing a quantitative approach (0.92). 16 In addition, we did not find significant differences among the 3 raters with different clinical backgrounds (radiologist, neurologist, and neuroscience researcher), even though each had extensive experience with amyloid PET interpretation. This suggests that the 3-step interpretation process may be robust enough for use across raters with different levels of imaging expertise.
Our study sample was composed of cognitively normal older adults with a prevalence of elevated cerebral amyloid-β plaque ranging from 25.5% at its lowest on Visual Reads to 45.5% at its highest on Quantitative Reads. These prevalence data align with estimates that approximately 30% of cognitively normal older adults have elevated cerebral amyloid-β plaque. 18 The broad variability in elevated amyloid-β plaque across these 3 different PET scan interpretation methods underscores the need for more precise interpretation processes. Although our study does not include long-term clinical outcomes or pathological confirmation of AD, the enhanced consistency across reads using the VisQ approach suggests this process provides a more stable measure than the Visual Read alone by reducing sources of variability inherent in subjective visual interpretation methods. This is particularly true for detection of early plaque deposition, as the PET scans with altered interpretations in this study had lower mean SUVRs than elevated scans that did not change.
The Quantitative Read estimate of 45.5% of individuals with elevated amyloid-β plaque is higher than expected in a cognitively normal study population. In at least 5 cases, elevated Quantitative Reads were unanimously determined by the raters to be nonelevated by both Visual and VisQ Reads. This suggests that the Quantitative Read threshold may be a good screening tool for detecting amyloid-β plaque, but not specific enough to make clinical inferences or management decisions. This is particularly important given the implications of an elevated or nonelevated PET scan for both individual patients and their clinicians. Further longitudinal clinical research is necessary to determine the relevance of elevated Quantitative Reads in the absence of visual elevations of amyloid-β plaque. Our cognitively normal sample population is unique for testing PET scan techniques for detecting early amyloid-β plaque deposition, as the prevalence of elevated plaque is lower than in populations with mild cognitive impairment and dementia, although this could potentially limit the generalizability of these results to the general population.
This study suggests that interpretation of florbetapir PET scans should combine visual and quantitative analyses, similar to PET/CT oncologic imaging when standardized uptake values (SUVs) are used in combination with visual interpretation to make final diagnostic decisions. Because most clinical florbetapir PET scans will be interpreted by diagnostic radiologists with varying degrees of expertise in the field, a standardized process is necessitated. As in other medical fields, developing a systematic approach to the interpretation of these scans improves sensitivity and specificity, as well as reduces interrater variability. Our study findings suggest that interpretation approaches for florbetapir PET scans, particularly in the cognitively normal population, use a systematic process that combines both visual and quantitative information, which will uniquely minimize variability from a singular approach of using either a qualitative-or quantitative-only method. Finally, the findings from this study may assist interpreting radiologists in 3 ways. First, if the Visual Read is initially nonelevated, careful analysis of the quantitative data is necessary and may change the final interpretation in approximately 10% of cases. This may be particularly important for inexperienced readers, who may utilize the quantitative data to direct their eye to subtle or equivocal regions of concern, to increase sensitivity and diminish variability between readers. Second, if the Visual Read is elevated and 5 or 6 regions are nonelevated on quantitative analysis, it is most likely a false-positive Visual Read, as the nonelevated Quantitative Read alone demonstrates a high negative predictive value. Finally, quantitative-only reads appear to be overly sensitive and not specific enough to interpret alone without close visual inspection by a trained radiologist.
Specific limitations of this study are the relatively small sample size (n = 55) and lack of a pathologic or tissue diagnosis as confirmation of the imaging findings. The relatively small sample will become more robust in anticipated longitudinal studies on the same individuals to evaluate for changes in their scan. There are obvious issues with obtaining a tissue biopsy on a cognitively normal participant, though, our results are at the expected frequency of elevated amyloid plaque reported elsewhere. 18 
CONCLUSIONS
Our study suggests that combining both visual and quantitative information improves interrater variability of florbetapir PET scan interpretations in individuals without clinically meaningful cognitive change. This approach may lead to earlier detection of amyloid-β plaque, which may have implications for primary prevention interventions as therapeutics become more widely available.
